223 related articles for article (PubMed ID: 27706930)
1. Bone-site-specific responses to zoledronic acid.
Vermeer J; Renders G; van Duin MA; Jansen I; Bakker LF; Kroon SA; de Vries TJ; Everts V
Oral Dis; 2017 Jan; 23(1):126-133. PubMed ID: 27706930
[TBL] [Abstract][Full Text] [Related]
2. Mevalonates restore zoledronic acid-induced osteoclastogenesis inhibition.
Nagaoka Y; Kajiya H; Ozeki S; Ikebe T; Okabe K
J Dent Res; 2015 Apr; 94(4):594-601. PubMed ID: 25535203
[TBL] [Abstract][Full Text] [Related]
3. Exposing human epithelial cells to zoledronic acid can mediate osteonecrosis of jaw: an in vitro model.
Saracino S; Canuto RA; Maggiora M; Oraldi M; Scoletta M; Ciuffreda L; Vandone AM; Carossa S; Mozzati M; Muzio G
J Oral Pathol Med; 2012 Nov; 41(10):788-92. PubMed ID: 22650360
[TBL] [Abstract][Full Text] [Related]
4. Jaw bone marrow-derived osteoclast precursors internalize more bisphosphonate than long-bone marrow precursors.
Vermeer JA; Jansen ID; Marthi M; Coxon FP; McKenna CE; Sun S; de Vries TJ; Everts V
Bone; 2013 Nov; 57(1):242-51. PubMed ID: 23962725
[TBL] [Abstract][Full Text] [Related]
5. Histopathological features of bisphosphonates related osteonecrosis of the jaw in rats with and without vitamin d supplementation.
Yanık S; Aras MH; Erkılıç S; Bozdağ Z; Demir T; Çetiner S
Arch Oral Biol; 2016 May; 65():59-65. PubMed ID: 26854621
[TBL] [Abstract][Full Text] [Related]
6. The effects of bisphosphonate on the remodeling of different irregular bones in mice.
Su J; Feng M; Han W; Zhao H
J Oral Pathol Med; 2015 Sep; 44(8):638-48. PubMed ID: 25370709
[TBL] [Abstract][Full Text] [Related]
7. Severe compromise of preosteoblasts in a surgical mouse model of bisphosphonate-associated osteonecrosis of the jaw.
Córdova LA; Guilbaud F; Amiaud J; Battaglia S; Charrier C; Lezot F; Piot B; Redini F; Heymann D
J Craniomaxillofac Surg; 2016 Sep; 44(9):1387-94. PubMed ID: 27519659
[TBL] [Abstract][Full Text] [Related]
8. Removal of matrix-bound zoledronate prevents post-extraction osteonecrosis of the jaw by rescuing osteoclast function.
Elsayed R; Abraham P; Awad ME; Kurago Z; Baladhandayutham B; Whitford GM; Pashley DH; McKenna CE; Elsalanty ME
Bone; 2018 May; 110():141-149. PubMed ID: 29408511
[TBL] [Abstract][Full Text] [Related]
9. Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling.
McDonald MM; Dulai S; Godfrey C; Amanat N; Sztynda T; Little DG
Bone; 2008 Oct; 43(4):653-62. PubMed ID: 18582604
[TBL] [Abstract][Full Text] [Related]
10. OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice.
de Molon RS; Shimamoto H; Bezouglaia O; Pirih FQ; Dry SM; Kostenuik P; Boyce RW; Dwyer D; Aghaloo TL; Tetradis S
J Bone Miner Res; 2015 Sep; 30(9):1627-40. PubMed ID: 25727550
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.
Daubiné F; Le Gall C; Gasser J; Green J; Clézardin P
J Natl Cancer Inst; 2007 Feb; 99(4):322-30. PubMed ID: 17312309
[TBL] [Abstract][Full Text] [Related]
12. The effect of bisphosphonate treatment on the biochemical and cellular events during bone remodelling in response to microinjury stimulation.
Mulcahy LE; Curtin CM; McCoy RJ; O'Brien FJ; Taylor D; Lee TC; Duffy GP
Eur Cell Mater; 2015 Nov; 30():271-81. PubMed ID: 26614482
[TBL] [Abstract][Full Text] [Related]
13. Implications of high-dosage bisphosphonate treatment on bone tissue in the jaw and knee joint.
Renders GA; Vermeer JA; Leung PM; Reynaert F; Prins C; Langenbach GE; Everts V
Calcif Tissue Int; 2014 Nov; 95(5):436-45. PubMed ID: 25183284
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid - related osteonecrosis of the jaws. Experimental model with dental extractions in rats.
Barba-Recreo P; Del Castillo Pardo de Vera JL; García-Arranz M; Yébenes L; Burgueño M
J Craniomaxillofac Surg; 2014 Sep; 42(6):744-50. PubMed ID: 24342733
[TBL] [Abstract][Full Text] [Related]
15. Increased numbers of nonattached osteoclasts after long-term zoledronic acid therapy in mice.
Kuroshima S; Go VA; Yamashita J
Endocrinology; 2012 Jan; 153(1):17-28. PubMed ID: 22109892
[TBL] [Abstract][Full Text] [Related]
16. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair.
Amanat N; McDonald M; Godfrey C; Bilston L; Little D
J Bone Miner Res; 2007 Jun; 22(6):867-76. PubMed ID: 17371160
[TBL] [Abstract][Full Text] [Related]
17. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment.
Mundy GR; Yoneda T; Hiraga T
Semin Oncol; 2001 Apr; 28(2 Suppl 6):35-44. PubMed ID: 11346863
[TBL] [Abstract][Full Text] [Related]
18. High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties.
Pozzi S; Vallet S; Mukherjee S; Cirstea D; Vaghela N; Santo L; Rosen E; Ikeda H; Okawa Y; Kiziltepe T; Schoonmaker J; Xie W; Hideshima T; Weller E; Bouxsein ML; Munshi NC; Anderson KC; Raje N
Clin Cancer Res; 2009 Sep; 15(18):5829-39. PubMed ID: 19737962
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates: mechanism of action and role in clinical practice.
Drake MT; Clarke BL; Khosla S
Mayo Clin Proc; 2008 Sep; 83(9):1032-45. PubMed ID: 18775204
[TBL] [Abstract][Full Text] [Related]
20. Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone.
Li X; Liao J; Park SI; Koh AJ; Sadler WD; Pienta KJ; Rosol TJ; McCauley LK
Bone; 2011 Jun; 48(6):1354-61. PubMed ID: 21419883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
